eligibility_summary
Adults ≥18 with histology-proven R/M salivary gland cancer not curable by surgery/RT, measurable disease (RECIST 1.1), ECOG 0–1, adequate counts/renal/hepatic function, contraception. Cohort 1: ACC, any prior therapy, progression within 6 mo. Cohort 2: SDC or int/high‑grade adenoCA NOS/MEC, ≤3 prior chemo, HER2+ requires prior HER2 therapy or contraindication. Exclude: recent RT/systemic therapy, active CNS disease, uncontrolled infection or major comorbidity, pregnancy, high‑dose steroids.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase II, single-arm study of sacituzumab govitecan (SG) in recurrent/metastatic salivary gland cancers (ACC, SDC/adeno-NOS/MEC). Drug/intervention: Sacituzumab govitecan is an antibody–drug conjugate (ADC): a humanized anti–TROP-2 IgG1 monoclonal antibody linked to SN-38, the active metabolite of irinotecan (a topoisomerase I–inhibiting cytotoxic). Mechanism of action: SG binds TROP-2 on tumor cells → internalization → intracellular release of SN-38 → topoisomerase I inhibition, DNA damage, S-phase arrest and apoptosis, membrane-permeable SN-38 enables bystander killing. IgG1 backbone may provide limited immune effector activity. Targets/cells/pathways: TROP-2–expressing epithelial tumor cells in salivary gland carcinomas, key pathways include TROP-2 signaling and DNA replication/topoisomerase I–dependent repair. Biomarker exploration includes predictors of response (e.g., TROP-2 levels).